119.70 +0.04 (0.03%)
After hours: 4:47PM EDT
|Bid||119.70 x 900|
|Ask||120.21 x 1100|
|Day's Range||118.61 - 121.91|
|52 Week Range||87.49 - 183.60|
|Beta (3Y Monthly)||3.06|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Bluebird Bio stock dipped Tuesday after an analyst noted manufacturing hiccups will prevent the biotech company from selling its gene therapy in Europe and the U.S. until 2020 and 2021, respectively.
bluebird bio Inc NASDAQ/NGS:BLUEView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for BLUE with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting BLUE. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding BLUE are favorable, with net inflows of $3.11 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and recouped their losses by the end of the first quarter. […]
Following European approval earlier this month, bluebird bio announced its beta-thalassemia gene therapy will launch with a sky-high price tag.
(BLUE) will sell a gene-therapy treatment for the disease beta-thalassemia for $1.8 million per patient, but the money won’t start coming in as soon as expected. The drug, Zynteglo—the second-most-expensive in the world, according to The Wall Street Journal—received conditional marketing authorization from the European Union early this month. The treatment has yet to be approved by the Food and Drug Administration.
Th Cambridge biotech set a price tag of $1.8 million spread over five years (315,000 euros per year, or the equivalent of $356,000 annually) for its first commercial drug on Friday, for which it received approval to sell in Europe last week.
Bluebird Bio plans to price a new gene therapy for people with an inherited blood disorder at almost $1.8m per patient, and will try to persuade European healthcare systems to shell out for it by promising to only seek full payment if it works. Healthcare systems will pay an initial instalment of €315,000 but will only pay more instalments if the treatment helps the patient avoid blood transfusions. The Boston-based biotech start-up’s drug is part of a class of new transformative therapies that need to be administered only once and apply to a small patient population.
Errant Gene Therapeutics claims in a new lawsuit that local venture capital firm Third Rock Ventures and bluebird bio CEO Nick Leschly worked to hinder its drug development efforts so it could obtain a key part of its intellectual property.
While bluebird bio, Inc. (NASDAQ:BLUE) shareholders are probably generally happy, the stock hasn't had particularly...
One of Massachusetts' leading life sciences venture capital firms has raised its largest ever fund, collecting $770 million to invest in new startups. Third Rock Ventures LLC closed its fifth fundraising this week, the company stated in a press release.
bluebird bio (BLUE) announces that the EC has granted conditional marketing authorization to Zynteglo, its first gene therapy, for patients aged 12 years or older with TDT, who do not have a specific genotype.
European regulators have signed off on the biotech's revolutionary gene therapy for beta-thalassemia.
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
This is the time of year when stocks are sleepy at best, and at worst, prone to pullbacks.That's not necessarily true of all equities, however. Some groups are very active and perform quite well in the summer months. Pharmaceutical stocks - and especially biotech stocks - fare pretty well this time of year.Part of that cyclical strength stems from how the Food and Drug Administration schedules key decision-making dates for new drugs. Another part of it may be the result of recurring industry conferences, where many drug-development updates are unveiled.Here are 11 biotech stocks and pharmaceutical companies to watch over the next few months. Because biotechnology companies' shares tend to hinge heavily on product updates, this seasonal tide of news could move their respective stocks well before (and even long after) the day the news is posted. Just be cautious; smaller biotechnology stocks with one or just a couple of trial products can move drastically on new data - for better or for worse. SEE ALSO: 20 Great Stocks That You Haven't Heard Of
Back in 1997, Paul Marshall and Ian Wace launched their own hedge fund called Marshall Wace. The fund is headquartered in London, England while providing additional offices in New York, and Hong Kong. The fund’s investment philosophy combines quantitative strategies with basic investment principles for the purpose of delivering strong returns to its clients. Its […]
These drugs and the biotechs that make them could be on the way to tremendous success in the near future.
Bluebird bio Inc (NASDAQ: BLUE ) held its Analyst Day in New York last week, and at least one analyst came away less bullish on the stock. The Analyst Wedbush's David Nierengarten downgraded bluebird bio ...
At least one analyst left (BLUE)’s (ticker: BLUE) analyst day last week concerned about the development-stage biotech firm’s pricing plans for its new gene therapy treatment. Bluebird Bio shares were down 2.7% when the market opened on Wednesday morning, following a report by Wedbush’s David Nierengarten, who downgraded his rating of the firm to Neutral from Outperform, with a 12-month price target of $166, to neutral, with a 12-month price target of $131. Bluebird Bio, which went public in 2013, develops high-priced cell and gene therapies that target rare illnesses.